Epoprostenol
(Synonyms: 依前列醇钠,Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan) 目录号 : GC12101
一键复制产品信息
Epoprostenol 是天然存在的花生四烯酸代谢物前列环素的合成类似物。
Cas No.:61849-14-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Epoprostenol is a synthetic analogue of the naturally occurring eicosanoid prostacyclin [1]. The inhibitory effect of epoprostenol on platelet aggregation is mediated by the stimulation of adenylate cyclase and the subsequent increase of cyclic adenosine monophosphate-3', 5' (cAMP) in platelets, leading to a rise in the intracellular levels of cyclic AMP [2]. Epoprostenol is widely used in studies on pulmonary arterial hypertension (PAH) to promote vascular dilation[3].
In vitro, Epoprostenol treatment for 24h at 1.0ng/ml induced apoptosis in PAH-pulmonary artery smooth muscle cells (PASMCs), resulting in increased cAMP levels and upregulated FasL expression[4].
References:
[1] Provencher S, Paruchuru P, Spezzi A, et al. Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertension[J]. PLoS One, 2015, 10(3): e0120657.
[2] Mohammadi A, Matos W F, Intriago C, et al. Use of Epoprostenol in the treatment of pulmonary arterial hypertension[J]. Cureus, 2021, 13(9).
[3] Sitbon O, Noordegraaf A V. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience[J]. European Respiratory Review, 2017, 26(143).
[4] Akagi S, Nakamura K, Matsubara H, et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension[J]. International journal of cardiology, 2013, 165(3): 499-505.
Epoprostenol 是天然存在的花生四烯酸代谢物前列环素的合成类似物[1]。Epoprostenol对血小板聚集的抑制作用是通过刺激腺苷酸环化酶，从而增加血小板中环磷酸腺苷-3', 5'（cAMP）的含量来实现的，这导致细胞内环磷酸腺苷水平升高[2]。Epoprostenol 被广泛用于肺动脉高压（PAH）的研究，以促进血管舒张[3]。
在体外，使用1.0ng/ml的Epoprostenol处理24小时，可诱导PHA-肺动脉平滑肌细胞（PASMCs）凋亡，导致cAMP水平升高和FasL表达上调[4]。
| Cell experiment [1]: | |
|
Cell lines |
Pulmonary artery smooth muscle cells (PASMCs) |
|
Preparation Method |
PASMCs were seeded in 6-well plates at a density of 5×105 cells/well. After incubation for 24h in DMEM medium supplemented with 10% Fetal bovine serum (FBS), Epoprostenol (0.1, 1, 5, and 10ng/ml) was added to the culture media. After incubation for 15minutes, cAMP was measured. |
|
Reaction Conditions |
0.1, 1, 5, and 10ng/ml; 15min |
|
Applications |
Epoprostenol treatment enhanced the production of cAMP in PASMCs. |
|
References: |
|
| Cas No. | 61849-14-7 | SDF | |
| 别名 | 依前列醇钠,Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan | ||
| 化学名 | sodium (E)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoate | ||
| Canonical SMILES | O[C@H]1[C@H](/C=C/[C@H](CCCCC)O)[C@@H](C/2)[C@H](C1)OC2=C\CCCC([O-])=O.[Na+] | ||
| 分子式 | C20H31NaO5 | 分子量 | 374.45 |
| 溶解度 | DMF: 5 mg/ml,DMSO: 5 mg/ml,Ethanol: 10 mg/ml*,PBS (pH >10.2): 10 mg/ml,Water: 10 mg/ml | 储存条件 | Desiccate at -80°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6706 mL | 13.3529 mL | 26.7058 mL |
| 5 mM | 534.1 μL | 2.6706 mL | 5.3412 mL |
| 10 mM | 267.1 μL | 1.3353 mL | 2.6706 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >96.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet